GSK sues Chinese company over Advair Diskus TMs
26-03-2019
GSK seeks to boost oncology repertoire with $5.1bn acquisition
03-12-2018
will barton / Shutterstock.com
Growth in GlaxoSmithKline’s (GSK) vaccines and consumer healthcare divisions has managed to partly counter the impact of generic versions of Advair (fluticasone propionate/salmeterol) on its sales.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
GSK, GlaxoSmithKline, Advair, generics, patent cliff, results, vaccines, Emma Walmsley, Tesaro, R&D
